Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
Tesamorelin vs. Semaglutide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceVery limited comparison
At least one comparison profile is still being completed. Use the underlying compound records for the evidence currently available.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
- Both have FDA-approved products for defined, product-specific indications.
⇄ Different
Biggest Difference
Tesamorelin is distinguished by tesamorelin stimulates the pituitary growth-hormone pathway. Controlled human evidence supports a narrow HIV-lipodystrophy indication; it is not approved as a general weight-loss drug; Semaglutide is distinguished by single GLP-1 receptor agonist with multiple approved injection and tablet products and mature outcomes evidence.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
Tesamorelin is distinguished in the current record by tesamorelin stimulates the pituitary growth-hormone pathway. Controlled human evidence supports a narrow HIV-lipodystrophy indication; it is not approved as a general weight-loss drug. Semaglutide is distinguished by single GLP-1 receptor agonist with multiple approved injection and tablet products and mature outcomes evidence. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceSemaglutide
Tesamorelin: Profile in progress. Semaglutide: Mature human evidence.
Regulatory historyComparable
Tesamorelin: FDA approved for a defined indication. Semaglutide: FDA approved for defined product-specific indications.
Mechanistic breadthComparable
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
Tesamorelin
- HIV-associated lipodystrophy
- Visceral abdominal fat
- Body composition
- HIV-associated NAFLD / MASLD
Semaglutide
- Weight management
- Type 2 diabetes
- Cardiovascular outcomes
- Chronic kidney disease
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
TesamorelinFDA approved for a defined indication
FDA approved for a defined indication
SemaglutideFDA-labeled indications
FDA approved in product-specific formulations for defined weight-management, type 2 diabetes, cardiovascular, kidney, and MASH indications.
Evidence depthEvidence, not a winner
TesamorelinProfile in progress
Two randomized Phase 3 trials enrolling 816 adults with HIV-associated abdominal fat accumulation.
SemaglutideMature Phase 3 + outcomes
Multiple large Phase 3 programs and outcomes trials, including SELECT, FLOW, ESSENCE, STEP TEENS, and the higher-dose STEP UP program.
Weight outcomesEvidence, not a winner
TesamorelinRecord incomplete
No dedicated weight-outcome summary has been editorially approved.
SemaglutidePeer-reviewed Phase 3
STEP 1 reported −14.9% mean change at 68 weeks with 2.4 mg versus −2.4% placebo. STEP UP later reported −18.7% with 7.2 mg, −15.6% with 2.4 mg, and −3.9% with placebo at 72 weeks.
Type 2 diabetesEvidence, not a winner
TesamorelinRecord incomplete
No dedicated diabetes-outcome summary has been editorially approved.
SemaglutideApproved + extensive trials
Approved injection and oral products have extensive type 2 diabetes evidence. Product names, routes, strengths, and label instructions are not automatically interchangeable.
Obstructive sleep apnoeaEvidence, not a winner
TesamorelinRecord incomplete
No dedicated obstructive-sleep-apnoea outcome summary has been editorially approved.
SemaglutideNo approved indication
No FDA-approved semaglutide indication for obstructive sleep apnoea was identified in the current U.S. labels.
Cardiovascular outcomesEvidence, not a winner
TesamorelinRecord incomplete
No dedicated cardiovascular-outcome summary has been editorially approved.
SemaglutideSELECT + labeled uses
SELECT demonstrated fewer major cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes. Other approved product labels cover defined diabetes populations.
Administration and handlingEvidence, not a winner
TesamorelinOpen profile
Open the compound profile for approved-label information or clearly identified trial-administration records.
SemaglutideMultiple product-specific labels
Current FDA labels include weekly subcutaneous injections and daily oral tablets with product-specific administration, switching, and storage instructions. Approved products require no reconstitution.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Very limited comparison
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Long-term cardiovascular safety and whether findings translate beyond the narrow populations studied.
- Long-term comparative outcomes across newer products and doses, rare events at population scale, and evidence outside studied populations or approved products.
Community Intelligence
Emerging patterns, clearly separated from evidence
Tesamorelin
No community experiences yetBe the first account holder to contribute.
Semaglutide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.